Literature DB >> 15299518

Crystallographic analyses of an active HIV-1 ribonuclease H domain show structural features that distinguish it from the inactive form.

D Chattopadhyay1, B C Finzel, S H Munson, D B Evans, S K Sharma, N A Strakalaitus, D P Brunner, F M Eckenrode, Z Dauter, C Betzel, H M Einspahr.   

Abstract

. An active recombinant preparation of the carboxy-terminal ribonuclease H (RNase H) domain of HIV-I reverse transcriptase has produced crystals of several different forms, including a trigonal prism form (P3(1); a = b = 52.03, c = 113.9 A with two molecules per asymmetric unit) and a hexagonal tablet form (P6(2)22 or P6(4)22; a = b = 93.5, c = 74.1 A with one molecule per asymmetric unit). The former appears to be isomorphous with crystals of a similar, but inactive, version of the enzyme that was used for a prior crystal structure determination [Davies, Hostomska, Hostomsky, Jordan & Matthews (1991). Science, 252, 88-95]. We have also obtained a structure solution for this crystal form and have refined it with 2.8 A resolution data (R = 0.216). We report here details of our crystallization studies and some initial structural results that verify that the preparation of active HIV-1 RNase H yields a protein that is not just enzymatically, but also structurally, distinguishable from the inactive form. Evidence suggests that region 538-542, which may be involved in the catalytic site and which is disordered in both molecules in the prior structure determination, is ordered in the crystal structure of the active enzyme, although the ordering may include more than one conformation for this loop. It should also be noted that, in the crystal structure of the trigonal form, RNase H monomers associate to form noncrystallographic twofold-symmetric dimers by fusing five-stranded mixed beta sheets into a single ten-stranded dimerwide sheet, an assembly that was not remarked upon by previous investigators.

Entities:  

Year:  1993        PMID: 15299518     DOI: 10.1107/S0907444993002409

Source DB:  PubMed          Journal:  Acta Crystallogr D Biol Crystallogr        ISSN: 0907-4449


  7 in total

1.  Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase.

Authors:  Anoma Somasunderam; Monique R Ferguson; Daniel R Rojo; Varatharasa Thiviyanathan; Xin Li; William A O'Brien; David G Gorenstein
Journal:  Biochemistry       Date:  2005-08-02       Impact factor: 3.162

2.  Determinants of Active-Site Inhibitor Interaction with HIV-1 RNase H.

Authors:  Zhaoyong Xi; Zhengqiang Wang; Stefan G Sarafianos; Nataliya S Myshakina; Rieko Ishima
Journal:  ACS Infect Dis       Date:  2019-10-02       Impact factor: 5.084

Review 3.  Murine leukemia virus reverse transcriptase: structural comparison with HIV-1 reverse transcriptase.

Authors:  Marie L Coté; Monica J Roth
Journal:  Virus Res       Date:  2008-02-21       Impact factor: 3.303

4.  Human immunodeficiency virus type-1 reverse transcriptase and ribonuclease H as substrates of the viral protease.

Authors:  A G Tomasselli; J L Sarcich; L J Barrett; I M Reardon; W J Howe; D B Evans; S K Sharma; R L Heinrikson
Journal:  Protein Sci       Date:  1993-12       Impact factor: 6.725

5.  Substitution of a highly basic helix/loop sequence into the RNase H domain of human immunodeficiency virus reverse transcriptase restores its Mn(2+)-dependent RNase H activity.

Authors:  J L Keck; S Marqusee
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

6.  A second hybrid-binding domain modulates the activity of Drosophila ribonuclease H1.

Authors:  Jose M González de Cózar; Maria Carretero-Junquera; Grzegorz L Ciesielski; Sini M Miettinen; Markku Varjosalo; Laurie S Kaguni; Eric Dufour; Howard T Jacobs
Journal:  J Biochem       Date:  2020-11-01       Impact factor: 3.387

7.  Phylogenomics reveals subfamilies of fungal nonribosomal peptide synthetases and their evolutionary relationships.

Authors:  Kathryn E Bushley; B Gillian Turgeon
Journal:  BMC Evol Biol       Date:  2010-01-26       Impact factor: 3.260

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.